CorMedix Inc. Form 4 March 02, 2017

## FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box subject to

if no longer Section 16. Form 4 or

Form 5 obligations

may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

(Print or Type Responses)

1. Name and Address of Reporting Person \* ARMSTRONG JR. JOHN L.

(First) (Last)

C/O CORMEDIX INC., 1430 U.S. HIGHWAY 206, SUITE 200

(Street)

(Middle)

(Month/Day/Year) 03/01/2017

Symbol

4. If Amendment, Date Original

CorMedix Inc. [CRMD]

3. Date of Earliest Transaction

Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to

Issuer

(Check all applicable)

**OMB APPROVAL** 

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Director 10% Owner X\_ Officer (give title Other (specify below) below)

Exec VP of Tech Operations

6. Individual or Joint/Group Filing(Check Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

(City) (State) (Zip)

1. Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) (Instr. 3)

BEDMINSTER, NJ 07921

Execution Date, if

(Month/Day/Year)

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8)

(Instr. 3, 4 and 5)

5. Amount of Securities Beneficially Owned Following

Reported Transaction(s)

(Instr. 3 and 4)

6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect Beneficial (T) (Instr. 4)

Ownership (Instr. 4)

Code V Amount (D) Price

(A)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security

Conversion or Exercise

3. Transaction Date 3A. Deemed (Month/Day/Year)

Execution Date, if any

4. 5. Number of **Transaction**Derivative Code Securities

6. Date Exercisable and **Expiration Date** (Month/Day/Year)

7. Title and Amount of **Underlying Securities** (Instr. 3 and 4)

### Edgar Filing: CorMedix Inc. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)		Acquired (A Disposed of (Instr. 3, 4, a 5)	(D) and				
				Code V	(A)		Date Exercisable	Expiration Date	Title	Amount Number Shares
Stock Option (Right to Buy Common Stock)	\$ 2.18	03/01/2017	03/01/2017	A	100,000		<u>(1)</u>	03/01/2027	Common Stock	100,00
Restricted Stock Units	<u>(2)</u>						(2)	02/28/2027	Common Stock	36,057
Stock Option (Right to Buy Common Stock)	\$ 1.52						(3)	11/14/2024	Common Stock	10,000
Stock Option (Right to Buy Common Stock)	\$ 3.25						<u>(4)</u>	07/28/2025	default	15,000
Stock Option (Right to Buy Common Stock)	\$ 2.51						<u>(5)</u>	03/08/2026	Common Stock	200,00

# **Reporting Owners**

Reporting Owner Name / Address	Relationships						
1	Director	10% Owner	Officer	Other			
ARMSTRONG JR. JOHN L. C/O CORMEDIX INC. 1430 U.S. HIGHWAY 206, SUITE 200 BEDMINSTER, NJ 07921			Exec VP of Tech Operations				

Reporting Owners 2

Edgar Filing: CorMedix Inc. - Form 4

## **Signatures**

/s/ Alexander M. Donaldson, by power of attorney

03/02/2017

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests based on certain performance milestones, subject to continued employment. The option will be forfeited if such milestones are not met by certain dates.
- (2) Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vest 50% on December 31, 2017 and 50% on December 31, 2018, subject to continued employment.
- (3) These options vested upon the achievement of certain milestones, subject to continued employment.
- (4) One third of these options vested upon the achievement of a certain milestone and one third vested on each of December 31, 2015 and July 28, 2015.
- (5) 15,000 of these options vest monthly over four years, beginning on March 9, 2016, 20,000 vest upon the achievement of a certain milestone, subject to continued employment, and the rest vested upon the achievement of certain milestones.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3